A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab

Annals of the Rheumatic Diseases

Volumn 76, Issue 3, 2017, Pages 526-533

  Kaur, Primal ^a   Chow, Vincent ^a   Zhang, Nan ^a   Moxness, Michael ^a   Kaliyaperumal, Arunan ^a   Markus, Richard ^a  

^a AMGEN INC   (United States)

Author keywords

Anti TNF; Pharmacokinetics; TNF alpha

Indexed keywords

ADALIMUMAB; ADALIMUMAB ATTO; DRUG ANTIBODY; ANTIBODY; ANTIRHEUMATIC AGENT; BIOSIMILAR AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BIOEQUIVALENCE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; DYSMENORRHEA; ELIMINATION HALF-LIFE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; IMMUNOGENICITY; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; NOSE OBSTRUCTION; OROPHARYNX PAIN; PARALLEL DESIGN; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SINUS CONGESTION; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; ADOLESCENT; BLOOD; CLINICAL TRIAL; EUROPE; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; THERAPEUTIC EQUIVALENCE; UNITED STATES; YOUNG ADULT;

ADALIMUMAB; ADOLESCENT; ADULT; ANTIBODIES; ANTIRHEUMATIC AGENTS; AREA UNDER CURVE; BIOSIMILAR PHARMACEUTICALS; EUROPE; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; SINGLE-BLIND METHOD; THERAPEUTIC EQUIVALENCY; UNITED STATES; YOUNG ADULT;

EID: 84979673341     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-208914     Document Type: Article

References (30)

1. Humira® (adalimumab). AbbVie Inc. 2015.
2. European Medicines Agency. Humira. Summary of product characteristics. 2015.
3. Dorner T, Strand V, Castaneda-Hernandez G, et al. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 2013;72:322-8.
4. Ventola CL. Biosimilars: Part 1: proposed regulatory criteria for FDA approval. P&T 2013;38:270-87.
5. Kozlowski S, Woodcock J, Midthun K, et al. Developing the nation's biosimilars program. N Engl J Med 2011;365:385-8.
6. US Food and Drug Administration. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. Rockville, MD, 2015. http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/ Guidances/UCM291128.pdf
7. US Food and Drug Administration. Guidance for industry: quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product. Rockville, MD, 2015. http://www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/guidances/ucm291134.pdf
8. US Food and Drug Administration. Clinical pharmacology data to support a demonstration of biosimilarity to a reference product. Rockville, MD, 2014. http:// www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ ucm397017.pdf
9. European Medicines Agency. Guideline on similar biological medicinal products. London, UK; 2014. Report No.: CHMP/437/04 rev 1.
10. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. London, UK, 2006. http://www.ema.europa. eu/docs/en-GB/document-library/Scientific-guideline/2015/01/WC500180219.pdf
11. Liu J, Eris T, Li C, et al. Assessing analytical similarity of proposed amgen biosimilar ABP 501 to adalimumab. BioDrugs 2016; doi:10.1007/s40259-016-0184-3
12. Velayudhan J, Chen Y-f, Rohrbach A, et al. Demonstration of functional similarity of proposed biosimilar ABP 501 to adalimumab. BioDrugs 2016; doi:10.1007/ s40259-016-0185-2
13. Kaur P, Chow VZ, N, MoxnessM, et al. Relationship between pharmacokinetics and antidrug antibody status of ABP 501, a biosimilar candidate to adalimumab. European League Against Rheumatism Annual European Conference April 22-26, 2015; Dublin, Ireland.
14. Tatarewicz S, Miller MJ, Zhou L, et al. Biosimilar immunogenicity assessment strategy. American Association of Pharmaceutical Scientists National Biotechnology Conference; 2014 May 19-21; San Diego, California; 2014.
15. Moxness M, Tatarewicz S, Weeraratne D, et al. Immunogenicity testing by electrochemiluminescent detection for antibodies directed against therapeutic human monoclonal antibodies. Clin Chem 2005;51:1983-5.
16. Shankar G, Devanarayan V, Amaravadi L, et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal 2008;48:1267-81.
17. US Food and Drug Administration. Bioavailability and bioequivalence studies for orally administered drug products - general considerations. Rockville, MD, 2003. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3995B1-07-GFI-BioAvail-BioEquiv.pdf
18. European Medicines Agency. Guideline on the investigation of bioequivalence. London, UK 2010. http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2010/01/WC500070039.pdf
19. Miyasaka N. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumatol 2008;18:252-62.
20. van de Putte LB, Rau R, Breedveld FC, et al. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis 2003;62:1168-77.
21. van der Bijl AE, Breedveld FC, Antoni CE, et al. An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clin Rheumatol 2008;27:1021-8.
22. Moller Dohn U, Boonen A, Hetland ML, et al. Erosive progression is minimal, but erosion healing rare, in patients with rheumatoid arthritis treated with adalimumab. A 1 year investigator-initiated follow-up study using high-resolution computed tomography as the primary outcome measure. Ann Rheum Dis 2009;68:1585-90.
23. Biologics Price Competition and Innovation Act of 2009. Washington, DC, 2009.
24. Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013;72:1605-12.
25. Wang SL, Hauenstein S, Ohrmund L, et al. Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay. J Pharm Biomed Anal 2013;78-79:39-44.
26. Lecluse LL, Driessen RJ, Spuls PI, et al. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol 2010;146:127-32.
27. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007;66:921-6.
28. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011;305:1460-8.
29. Radstake TR, Svenson M, Eijsbouts AM, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009;68:1739-45.
30. Vincent FB, Morand EF, Murphy K, et al. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2013;72:165-78.